MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Although the mechanism underlying the effects of VEGF-targeted therapies in Xp11.2 tRCC is largely unknown, a few studies have provided insight into the mechanism underlying the effects of mTOR inhibitors [25].